Sameek Roychowdhury, MD, PhD
Department of Internal Medicine, Division of Medical Oncology
Department of Pharmacology
Comprehensive Cancer Center, The Ohio State University
Biomedical Research Tower, Room 508
460 West 12th Ave
Columbus, Ohio 43210
Dr. Roychowdhury is a physician scientist in medical oncology interested in translational genomics and personalized cancer trials. His clinical practice in medical oncology includes patients with advanced cancer including prostate, colorectal, soft tissue sarcoma, and rare cancer subtypes.
The overarching goal of the lab is to identify putative predictive genomic biomarkers for targeted therapies and understand primary and secondary resistance mechanisms for these therapies. The lab utilizes next generation sequencing strategies including exome, RNAseq, and targeted capture sequencing for the development of genomics-driven clinical trials and characterization of resistance. The lab runs a study “Personalized Oncology Through High-Throughout Sequencing” that evaluates individual patients with advanced cancer considering clinical trials, and seeks to identify “driving” mutations that provide molecular eligibility for novel molecularly targeted therapies in development at Ohio State. We are studying the development of primary and secondary resistance for targeted therapies against activating mutations in PI3Kinase, FGFR, BRAF, CDK pathways through preclinical models and sequential clinical samples from clinical trials.
Projects include 1) molecular diagnostics for genomics-driven trials, 2) resistance to BRAF in rare cancers, 3) resistance to FGFR inhibitors in FGFR aberrant cancers, 4) and cancer genomics discovery projects in rare, poorly characterized cancers.